Evidence map›Paper›PMID 39061051›Full record

ArticleBMC public health2024

Epidemiological and clinical characteristics of long COVID-19 among Iranians: A community-based study in southern Iran.

Mehrdad Askarian, Erfan Taherifard, Fatemeh Jazzabi, Zahra Shayan, Ojan Assadian, Gary Groot, Nahid Hatam, Ardalan Askarian, Seyed Mohammadebrahim Faghihi, Ehsan Taherifard

Abstract read
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mehrdad AskarianDepartment of Community Medicine, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Erfan TaherifardMD-MPH Department, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Fatemeh JazzabiStudent Research Committee, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra ShayanDepartment of Biostatistics, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Ojan AssadianInstitute for Skin Integrity and Prevention, Regional Hospital Wiener Neustadt, Wiener Neustadt, Lower Austria, Austria.
Gary GrootDepartment of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada.
Nahid HatamDepartment of Community Medicine, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Ardalan AskarianCollege of Arts & Science, University of Saskatchewan, Saskatoon, Canada.
Seyed Mohammadebrahim FaghihiStudent Research Committee, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
Ehsan TaherifardStudent Research Committee, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran. Etaherim123@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe study aimed to evaluate the prevalence and pattern of long COVID-19 (LC) symptoms among individuals who had contracted COVID-19, to calculate the incidence of LC, and to provide insights into risk factors associated with developing LC in this population.

methodsThis population-based cross-sectional survey was conducted in Fars province in 2023. Adult participants with a history of COVID-19 were recruited using a cluster random sampling method, alongside a control group with similar characteristics through the same methodology. Data were collected through in-person interviews using two researcher-developed data collection forms focused on demographic and clinical information.

resultsA total of 2010 participants, comprising 1561 (77.7%) and 449 (22.3%) individuals with and without a previous history of COVID-19 were included. Among those with COVID-19 history, the prevalence of experiencing any symptoms was 93.7% (95% CI of 92.3%-94.8%) during the disease acute phase and 36.4% (95% CI of 34.0%-38.8%) after recovery. The incidence of symptoms specifically related to COVID-19, calculated by comparing the symptom rates between participants with and without a history of COVID-19, was found to be 13%. Factors such as older age, previous hospitalization for COVID-19, presence of cardiovascular disease, and use of steroids/chemotherapy were associated with LC symptoms.

conclusionsOur investigation sheds light on long-term aspects of COVID-19, demonstrating a significant prevalence of LC with diverse manifestations. It also underscores the importance of establishing standardized criteria and control groups in research on LC to address challenges related to heterogeneity and potential overestimation of symptoms.

Indexed as

COVID-19Post-Acute COVID-19 SyndromeAdultAgedCross-Sectional StudiesFemaleHumansIncidenceIranMaleMiddle AgedMiddle Eastern PeoplePrevalenceRisk FactorsYoung AdultLong COVID-19Post-Acute, SymptomsPost-COVID-19 ConditionSARS-CoV-2

Identifiers

PMID39061051
PMCPMC11282730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.